• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.

作者信息

Krečak Ivan, Ruščić Ivana, Zlatović Josipa Jović, Šupe Marijana, Krečak Marija Valovičić, Gverić-Krečak Velka

机构信息

Department of Internal Medicine, General Hospital of Šibenik-Knin County, Stjepana Radića 83, 22000, Šibenik, Croatia.

Polyclinic Medikol, Split, Croatia.

出版信息

Ann Hematol. 2021 Jun;100(6):1623-1624. doi: 10.1007/s00277-020-04369-9. Epub 2021 Jan 6.

DOI:10.1007/s00277-020-04369-9
PMID:33404692
Abstract
摘要

相似文献

1
Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.一名复发多发性骨髓瘤患者的副肿瘤性主动脉炎经达雷妥尤单抗、硼替佐米和地塞米松成功治疗。
Ann Hematol. 2021 Jun;100(6):1623-1624. doi: 10.1007/s00277-020-04369-9. Epub 2021 Jan 6.
2
[New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment].[欧洲新获批药物：卡非佐米联合达雷妥尤单抗及地塞米松用于一线治疗后难治性或复发性多发性骨髓瘤]
Bull Cancer. 2021 Jun;108(6):563-565. doi: 10.1016/j.bulcan.2021.04.005. Epub 2021 May 19.
3
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.低剂量维奈托克联合硼替佐米、达雷妥尤单抗和地塞米松治疗复发/难治性多发性骨髓瘤患者的单中心回顾性研究。
Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14.
4
[Daratumumab for multiple myeloma].达雷妥尤单抗用于治疗多发性骨髓瘤
Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.
5
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.达雷妥尤单抗、硼替佐米和地塞米松与硼替佐米和地塞米松治疗中国复发/难治性多发性骨髓瘤患者的比较：III 期 LEPUS（MMY3009）研究。
Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. doi: 10.1016/j.clml.2021.04.012. Epub 2021 Apr 24.
6
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.塞利尼索、硼替佐米与地塞米松（SVD方案）用于多次治疗后的复发难治性多发性骨髓瘤
Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.
7
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.达雷妥尤单抗和卡非佐米概述以及最近批准的达雷妥尤单抗、卡非佐米和地塞米松方案用于复发/难治性多发性骨髓瘤。
Expert Rev Hematol. 2021 Jan;14(1):31-45. doi: 10.1080/17474086.2021.1858790. Epub 2020 Dec 17.
8
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.达雷妥尤单抗、硼替佐米和地塞米松与硼替佐米和地塞米松治疗既往治疗的多发性骨髓瘤患者：CASTOR 的 3 年随访结果。
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. doi: 10.1016/j.clml.2019.09.623. Epub 2019 Oct 9.
9
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.硼替佐米联合地塞米松方案中添加达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的经济学评价：基于 CASTOR 最新更新分析。
Clin Ther. 2020 Feb;42(2):251-262.e5. doi: 10.1016/j.clinthera.2019.12.007. Epub 2020 Jan 20.
10
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.五例既往接受抗 C38 达妥木单抗治疗的复发多发性骨髓瘤患者中抗-CD38 依沙妥昔单抗联合泊马度胺和地塞米松的疗效：病例系列。
Hematology. 2022 Dec;27(1):204-207. doi: 10.1080/16078454.2022.2028978.

本文引用的文献

1
Association of Multiple Myeloma and Giant Cell Arteritis - A Case Report.多发性骨髓瘤与巨细胞动脉炎的关联——一例报告
Eur J Case Rep Intern Med. 2020 Jan 7;7(1):001360. doi: 10.12890/2020_001360. eCollection 2020.